Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

r 90 percent of patients remained on a once-daily dosing throughout the 6-month trial.
Both groups had a significant improvement in glycemic control, with no increases in hypoglycemia (major hypoglycemic events were .02 event/patient/month for both groups) and minimal weight change (.2 kg for 303 Algorithm group and -.3 kg for Standard-of-Care group).
About Levemir®
Levemir® (insulin detemir [rDNA origin] injection) is a long-acting insulin analog indicated for once- or twice-daily subcutaneous administration for the treatment of adults and children with Type 1 diabetes mellitus and adult patients with Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Levemir® has a relatively flat action profile with up to 24 hours duration of action. It can be added to oral anti-diabetic agents, or used in combination with a rapid-acting insulin. Levemir® is available in FlexPen®, a prefilled disposable insulin pen for easy, discreet dosing and in vials.

Levemir® was approved by the U.S. Food and Drug Administration in June 2005 and was launched in the U.S. in March 2006. Levemir® has been available for use in Europe since March 2004 and is currently approved in 50 countries worldwide. Levemir® is contraindicated in patients hypersensitive to insulin detemir or its excipients. Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with all insulins, the timing of hypoglycemic events may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Other adverse events commonly associated with insulin therapy may include injection site reactions (on average 3-4 percent of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

Any change of insulin dose should be made cautiously and only under medical supervision. C
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/27/2014)... Laboratories, Inc. (Nasdaq: CBRX ) ("Columbia" or ... manufacturing, and advanced analytical and consulting services to the ... the upcoming Rodman & Renshaw 16 th Annual ... New York . The Company will present at ... the New York Palace Hotel. To ...
(Date:8/27/2014)... 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the ... for the quarter of $240,156 compared to net income of ... For the nine months ended June 30, 2014: ...
(Date:8/27/2014)... PASADENA, Calif. , Aug. 27, 2014  After ... Compensation and Personal Injury billing solution for medical ... extremely positive response toward the new software. ... Development Sandy Thompson . "The sheer number of ... how true the need was for these types of ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... Inc. (ReGen), manufacturer of the popular and successful Menaflex Collagen ... (FDA) offer of a hearing under 21 CFR Part 16 ... the device. According to ReGen Chair and CEO ... FDA over the past six years makes it clear that ...
... 2011 Terso Solutions, Inc. has expanded its line ... refrigerator that is well-suited for hospital and laboratory ... new refrigerator makes better use of space, reduces energy ... such as reagents, cardiovascular products, tissue samples, and orthopedic ...
Cached Medicine Technology:ReGen to FDA: 'Thanks, But No Thanks' 2ReGen to FDA: 'Thanks, But No Thanks' 3ReGen to FDA: 'Thanks, But No Thanks' 4Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2
(Date:8/28/2014)... (PRWEB) August 28, 2014 MarijuanaDoctors.com is ... physician, James Patel M.D. of Livermore, California. As always, ... and most qualified physicians, and in accordance with that, ... patients to Dr. Patel’s practice. , Initially finding his ... young age, Dr. Patel was shaped by his mother’s ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... 2014 Author and orthopedic surgeon William ... on the thrilling adventures of sharp and witty ... is gearing up for a new marketing push in ... novellas , “Prescription: Murder” follows the adventures of ... dodging assassination attempts and thwarting criminals. In the first ...
(Date:8/27/2014)... 28, 2014 Recently, BambooIndustry.com, an innovative company ... announced that new bamboo panels are now offered ... deep discounts for clients worldwide. All people that place an ... rate, from 10 to 30 percent off. , The ... panels. “At the moment, all our new and old customers ...
(Date:8/27/2014)... National Resident Matching Program International (NRMPI) ... Education in Europe (AMEE) Conference being held at the ... September 3, 2014. As an exhibitor, NRMPI will ... share the benefits of its matching services, and discuss ... countries throughout the world. , “Exhibiting at ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , A Public Briefing, Saturday, September 19, 2009 , ... , 529 14th Street, NW , Washington D.C. 20045 ... number of organizations are joining in briefings on health care reform that would ... individual rights and choices of Americans. This will provide a stark contrast ...
... UNION CITY, Calif., Sept. 9 Abaxis, Inc. (Nasdaq: ... systems, announced today that Clint Severson, chairman and chief executive officer, ... 2009 on Thursday, September 17, 2009 at 10:00 a.m. ET. The ... New York City. , , About Abaxis ...
... , , , CHICAGO, ... to the long-term care industry, today announced it was named to ... privately held companies in the United States for the third consecutive year. ... 2005 through 2008 and is the only long-term care pharmacy services provider ...
... , CHAPEL HILL, N.C., Sept. 9 TSI ... healthcare information technology, was recently recognized in Inc. Magazine,s ... nation. Some of the most successful and innovative businesses in America ... SAS, Intuit, and Nike. , , ...
... , , CINCINNATI, Sept. 9 ... know that healthful aging depends on our current habits. "Our ... take precautionary measures to strengthen ourselves," explains the women,s health expert ... are all areas that are often overlooked or taken for granted ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Joint Briefing on Proposed Health Care Reform 2Health News:Joint Briefing on Proposed Health Care Reform 3Health News:Millennium Pharmacy Systems Named to Inc. 500 for Third Consecutive Year 2Health News:TSI Healthcare Recognized by Inc. Magazine 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 2Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 3Health News:Leading Women's Health Expert Offers Preventive Tips for Healthful Aging 4
Black multi-pinhole occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
49 pinholes, black...
Medicine Products: